Pfizer CEO Albert Bourla, BioNTech CEO Ugur Sahin

UK grants Pfiz­er, BioN­Tech his­toric first OK for mR­NA vac­cine, ex­pects mil­lions of dos­es by year end

Pfiz­er and BioN­Tech have scored a his­toric OK for their Covid-19 vac­cine in the UK, where the first dos­es are ex­pect­ed to be de­liv­ered with­in days.

Days af­ter the British gov­ern­ment au­tho­rized its Med­i­cines & Health­care Prod­ucts Reg­u­la­to­ry Agency to make a call in­de­pen­dent of the Eu­ro­pean Union — from which it’s in the process of ex­it­ing — the reg­u­la­tors gave the green light for emer­gency use of BNT162b2.

It marks the first time an mR­NA vac­cine has been sanc­tioned for wide­spread dis­tri­b­u­tion.

While Rus­sia and Chi­na have each start­ed ad­min­is­ter­ing home­grown vac­cines, they all lack the late-stage da­ta that Pfiz­er and Mod­er­na have of­fered to prove their shot works: In a 44,000-per­son tri­al, in­ves­ti­ga­tors record­ed 170 cas­es of Covid-19, of which on­ly 8 were in the vac­cine group. That trans­lat­ed to a 95% ef­fi­ca­cy for the 2-dose reg­i­men, bol­stered by pos­i­tive safe­ty re­sults with 2 months of me­di­an fol­low-up.

“We be­lieve that the roll-out of the vac­ci­na­tion pro­gram in the U.K. will re­duce the num­ber of peo­ple in the high-risk pop­u­la­tion be­ing hos­pi­tal­ized,” BioN­Tech CEO and co-founder Ugur Sahin said in a state­ment, adding:”The da­ta sub­mit­ted to reg­u­la­to­ry agen­cies around the world are the re­sult of a sci­en­tif­i­cal­ly rig­or­ous and high­ly eth­i­cal re­search and de­vel­op­ment pro­gram.”

FDA and EMA de­ci­sions are ex­pect­ed lat­er in De­cem­ber. The US agency like­ly won’t have a fi­nal ver­dict be­fore Dec 10, when an ad­vi­so­ry com­mit­tee is con­ven­ing to dis­cuss the emer­gency use au­tho­riza­tion.

Eu­ro­pean reg­u­la­tors and law­mak­ers ap­par­ent­ly aren’t im­pressed with the speed, crit­i­ciz­ing the move as “hasty.” In a state­ment to Reuters, the EMA said it has a more ap­pro­pri­ate pro­ce­dure that is longer be­cause it takes more ev­i­dence in­to ac­count and in­volves more checks. It ex­pects to de­cide by Dec 29.

But the MHRA stood by its process, and BioN­Tech ex­ecs said the UK agency had asked ques­tions to the same lev­el of de­tail as their in­ter­na­tion­al coun­ter­pars. Hav­ing first teamed up on the un­prece­dent­ed de­vel­op­ment ef­fort, Pfiz­er and BioN­Tech start­ed a rolling sub­mis­sion at the MHRA in late Oc­to­ber, lat­er than they went to the EMA.

In a state­ment, they em­pha­sized that ob­served ef­fi­ca­cy in adults age 65 or over — a key, vul­ner­a­ble group that will al­so like­ly be pri­or­i­tized for vac­ci­na­tion — is more than 94%. UK reg­u­la­tors al­so re­viewed chem­istry, man­u­fac­tur­ing and con­trol da­ta be­fore giv­ing out the OK.

In a state­ment, Pfiz­er CEO Al­bert Bourla ap­plaud­ed the MHRA “for their abil­i­ty to con­duct a care­ful as­sess­ment and take time­ly ac­tion to help pro­tect the peo­ple of the U.K.”

The next chal­lenge will be get­ting the vac­cines to hos­pi­tals and clin­ics ef­fi­cient­ly. Ex­perts and an­a­lysts have ex­pressed con­cerns about rolling out a vac­cine that re­quires stor­age at -70 de­grees Cel­sius (-94 Fahren­heit), but Pfiz­er and BioN­Tech say they have in­vest­ed in the in­fra­struc­ture, from freez­er box­es to char­ter flights, to get them where they need to be.

Each vial, BioN­Tech COO Sean Marett added in a press con­fer­ence, con­tains 5 dos­es that need to be di­lut­ed with saline so­lu­tion at the point of ad­min­is­tra­tion. Trans­port stud­ies they have con­duct­ed with Pfiz­er sug­gest­ed that the vac­cine can re­tain sta­bil­i­ty in trans­port at 2-8 de­grees Cel­sius for up to 6 hours, for de­liv­ery from vac­ci­na­tion hubs to satel­lite sites such as care homes.

When asked why their shot re­quires tougher cold chain con­di­tions than Mod­er­na’s, Sahin not­ed that sta­bil­i­ty stud­ies are still on­go­ing and they’re ex­pect­ing more da­ta in Jan­u­ary or Feb­ru­ary that might sup­port up­dat­ing the re­quire­ments.

“So there should be no big dif­fer­ences be­tween the dif­fer­ent mes­sen­ger RNA vac­cines, but the da­ta needs to be gen­er­at­ed,” he said. “We have just to un­der­stand that our can­di­date was se­lect­ed end of Ju­ly for this clin­i­cal tri­al — we had mul­ti­ple can­di­dates and we want­ed to iden­ti­fy the best can­di­date — So the sta­bil­i­ty stud­ies for this can­di­date start­ed sig­nif­i­cant­ly lat­er than the da­ta that were al­ready avail­able for oth­er can­di­dates.”

With a sup­ply deal al­ready in place for 40 mil­lion dos­es, the UK au­tho­riza­tion opens the door to phased de­liv­ery through­out 2020 and 2021. The com­pa­nies say the first dos­es should ar­rive from Pfiz­er’s fa­cil­i­ty in Bel­gium with­in a few days, whether by lor­ry or plane. Health Sec­re­tary Matt Han­cock said on BBC Ra­dio 4 that he ex­pects “a mat­ter of mil­lions of dos­es for the whole of the UK by the end of the year.”

Based on a pri­or­i­ti­za­tion guid­ance pre­pared by the Joint Com­mit­tee on Vac­ci­na­tion and Im­mu­ni­sa­tion, the 66 mil­lion-plus UK res­i­dents should re­ceive the vac­cine in the fol­low­ing or­der:

  • old­er adults’ res­i­dent in a care home and care home work­ers
  • all those 80 years of age and over and health and so­cial care work­er
  • all those 75 years of age and over­all those 70 years of age and over
  • all those 65 years of age and over­high-risk adults un­der 65 years of age
  • mod­er­ate-risk adults un­der 65 years of age
  • all those 60 years of age and over
  • all those 55 years of age and over
  • all those 50 years of age and over
  • rest of the pop­u­la­tion (pri­or­i­ty to be de­ter­mined)

So how does it feel to have the first vac­cine emer­gency ap­proval backed by Phase III da­ta?

“Ac­tu­al­ly I don’t think we’ve had time to think about it be­cause we’re too busy pack­ing vials for ship­ping to the UK with our col­leagues at Pfiz­er,” Marett said.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

Stéphane Bancel, Moderna CEO

'This is not go­ing to be good': Mod­er­na CEO Ban­cel warns of a 'ma­te­r­i­al drop' in vac­cine ef­fi­ca­cy as Omi­cron spreads

Even as public health officials remain guarded about their comments on the likelihood Omicron will escape the reach of the currently approved Covid-19 vaccines, there’s growing scientific consensus that we’re facing a variant that threatens to overwhelm the vaccine barricades that have been erected.

Stéphane Bancel, the CEO of Moderna, one of the leading mRNA players whose quick vault into the markets with a highly effective vaccine created an instant multibillion-dollar market, added his voice to the rising chorus early Tuesday. According to Bancel, there will be a significant drop in efficacy when the average immune system is confronted by Omicron. The only question now is: How much?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Ap­peals court puts the fi­nal nail in the cof­fin for Tec­fidera patent, adding to Bio­gen's bur­geon­ing set­backs

In another setback for Biogen, the big biotech lost its appeal to revive a patent for the once-blockbuster drug Tecfidera, marking a likely conclusion to the case.

The US Court of Appeals for the Federal Circuit issued the ruling Tuesday morning, saying Biogen failed to satisfy the “written description” requirement for patent law. As a result, Mylan-turned-Viatris will be able to sell its multiple sclerosis generic without fear of infringement and Biogen will have to find a new revenue driver elsewhere.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Philip Dormitzer, new GSK global head of vaccines R&D

Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

GlaxoSmithKline has appointed Philip Dormitzer, formerly chief scientific officer of Pfizer’s viral vaccines unit, as its newest global head of vaccines R&D, looking to leverage one of the leading minds behind Pfizer and BioNTech’s RNA collaboration that led to Covid-19 jab Comirnaty, the British drug giant said Tuesday.

Dormitzer had been with Pfizer for a little more than six years, joining up after a seven-year stint with Novartis, where he reached the role of US head of research and head of global virology for the company’s vaccines and diagnostics unit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

In­tro­duc­ing End­points Stu­dio, a new way to ad­ver­tise with End­points-craft­ed brand­ing cam­paigns

Since our start in 2016, Endpoints has grown fast while executing our mission to cover biopharma’s most critical developments for industry pros worldwide. As readership has grown, our advertising business has too. Endpoints advertising partners support the mission and engage their desired audiences through announcements on our email and web platforms, brand recognition in our event coverage and sponsorships of Endpoints daily and weekly reports.

FDA can­cels ODAC meet­ing this week to re­view two more dan­gling ac­cel­er­at­ed ap­provals — but won't ex­plain why

The FDA’s Oncologic Drugs Advisory Committee has decided to cancel a planned meeting on Thursday to discuss two cancer drugs that previously won accelerated approvals but failed to confirm clinical benefit in required follow-up trials or have taken a long time to finish those trials.

The FDA said in a statement that the meeting “is no longer needed” but did not offer further detail on why exactly it was canceled, telling Endpoints News to contact the companies. Attempts to contact both Secura Bio and Acrotech went unreturned. The companies may have decided to pull these treatments from the market, or they’ve come to new agreements with the agency on their confirmatory trials.

How to use reg­istry da­ta to sup­port FDA de­ci­sion mak­ing: Agency ex­plains in new guid­ance

Drugmakers looking to design a new registry or use an existing one to support a regulatory decision on a drug’s effectiveness or safety will need to consult with a new draft guidance released Monday by the FDA.

The agency’s reliance on registry data for regulatory decisions dates back more than two decades, at least, as in 1998 Bayer won approval for its anticoagulant Refludan (withdrawn from the market in 2013 for commercial reasons) based in part on a historical control group pulled from a registry.

Covid-19 roundup: As­pen to pro­duce gener­ic J&J vac­cine for Africa; First boost­ers for un­der-18-year-olds could come next week — re­port

After some ups and downs surrounding the manufacturing of J&J’s Covid-19 vaccine as the South African company’s site, Aspen Pharmacare has announced an agreement with the pharma to make and sell an Aspen-branded Covid-19 vaccine through the continent.

The agreement will expand the already-existing tech transfer and agreement to give Aspen the right to make vaccines from drug substance supplied by J&J, and sell the finished form under the name Aspenovax to public sector markets in Africa.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Tillman Gerngross (Adagio)

Till­man Gern­gross on Omi­cron: 'It is a grim sit­u­a­tion...we’re go­ing to see a sig­nif­i­cant drop in vac­cine ef­fi­ca­cy'

Tillman Gerngross, the rarely shy Dartmouth professor, biotech entrepreneur and antibody expert, has been warning for over a year that the virus behind Covid-19 would likely continue to mutate, potentially in ways that avoid immunity from infection and the best defenses scientists developed. He spun out a company, Adagio, to build a universal antibody, one that could snuff out any potential mutation.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.